Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Similar articles for PubMed (Select 22906900)

1.

Antiplatelet therapy in acute coronary syndrome and atrial fibrillation: aspirin.

Tanguay JF.

Adv Cardiol. 2012;47:20-30. doi: 10.1159/000338056. Epub 2012 Aug 9. Review.

PMID:
22906900
2.

Why we should not skip aspirin in cardiovascular prevention.

Schrör K.

Hamostaseologie. 2015 Apr 20;35(20150420). [Epub ahead of print]

PMID:
25891122
3.

Primary prevention of coronary artery disease by aspirin.

Taylor J.

Eur Heart J. 2015 Feb 21;36(8):467-8. No abstract available.

PMID:
25870873
4.

Difficult decision making in the management of patients with atrial fibrillation and acute coronary syndrome or invasive cardiovascular interventions: new recommendations for daily practice.

Boriani G, Lane DA, Windecker S, Huber K, Kirchhof P, Lip GY.

Europace. 2015 Feb 12. pii: euu303. [Epub ahead of print] No abstract available.

PMID:
25678602
5.

Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation.

Ben Freedman S, Gersh BJ, Lip GY.

Eur Heart J. 2015 Mar 14;36(11):653-6. doi: 10.1093/eurheartj/ehu494. Epub 2014 Dec 29. Review. No abstract available.

PMID:
25548061
6.

The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders.

Cohen AT, Imfeld S, Markham J, Granziera S.

Thromb Res. 2015 Feb;135(2):217-25. doi: 10.1016/j.thromres.2014.11.036. Epub 2014 Dec 13. Review.

PMID:
25541030
7.

Poverty, development and cardiovascular trials: more questions than answers?

Banerjee A.

Heart. 2015 Feb;101(4):245-7. doi: 10.1136/heartjnl-2014-306946. Epub 2014 Dec 23. No abstract available.

PMID:
25538135
8.

Aspirin: still a wonder drug? Sorting out aspirin's role in heart attack and stroke prevention.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2014 Aug;26(7):1-2. No abstract available.

PMID:
25300070
9.

Acute coronary syndromes: Risk of major coronary events not reduced by darapladib therapy.

Duarte JH.

Nat Rev Cardiol. 2014 Nov;11(11):621. doi: 10.1038/nrcardio.2014.148. Epub 2014 Sep 16. No abstract available.

PMID:
25223450
10.

[Multifactorial intervention to improve therapeutic compliance and secondary prevention measures after acute coronary syndrome].

Divisón JA, Escobar Cervantes C, Seguí Díaz M.

Semergen. 2014 Jul-Aug;40(5):274-5. doi: 10.1016/j.semerg.2014.05.007. Epub 2014 Jun 26. Spanish. No abstract available.

PMID:
24974305
11.

Antiplatelet and anticoagulation therapy for acute coronary syndromes.

Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA.

Circ Res. 2014 Jun 6;114(12):1929-43. doi: 10.1161/CIRCRESAHA.114.302737. Review.

12.

FDA questions use of aspirin for primary prevention of stroke and heart attack.

McCarthy M.

BMJ. 2014 May 8;348:g3168. doi: 10.1136/bmj.g3168. No abstract available.

PMID:
24812098
13.

Evidence-based medicine, pharmacogenetics, and antiplatelet therapy decision making for acute coronary syndrome.

Wong JB.

Ann Intern Med. 2014 Feb 18;160(4):284-5. No abstract available.

PMID:
24727845
14.

A Swedish powerhouse of clinical research.

Shurlock B.

Eur Heart J. 2014 Feb;35(5):261-2.

15.

Antiplatelet therapy in women with acute coronary syndrome.

Foody J.

J Fam Pract. 2014 Feb;63(2 Suppl):S3-8. Review. No abstract available.

PMID:
24527482
16.

A persisting dilemma for triple antithrombotic therapy: are we close to finding the correct answer?

Aytürk M, Sunman H, Yeter E.

J Am Coll Cardiol. 2014 Jul 15;64(2):231. doi: 10.1016/j.jacc.2013.10.089. Epub 2014 Feb 5. No abstract available.

PMID:
24509279
17.

Reply: A persisting dilemma for triple antithrombotic therapy: are we close to finding the correct answer?

Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Køber L, Torp-Pedersen C, Hansen ML.

J Am Coll Cardiol. 2014 Jul 15;64(2):231-2. doi: 10.1016/j.jacc.2013.11.049. Epub 2014 Feb 5. No abstract available.

PMID:
24509278
18.

Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade.

Atar D, Bode C, Stuerzenbecher A, Verheugt FW.

Fundam Clin Pharmacol. 2014 Aug;28(4):353-63. doi: 10.1111/fcp.12063. Epub 2014 Mar 10. Review.

19.

Dabigatran and myocardial infarction: a foggy scenario.

Pontillo D, Patruno N.

Vasc Health Risk Manag. 2014 Jan 20;10:45-8. doi: 10.2147/VHRM.S57529. eCollection 2014. No abstract available.

20.

[Antiplatelet agents and older patients: which drugs and what evidence?].

Reny JL, Roffi M, Fontana P.

Rev Med Suisse. 2013 Nov 6;9(405):2034-8. French.

PMID:
24308139
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk